Feb. 26 Quick Takes: Venrock leads Artiva’s crossover-laden $120M series B; plus Roivant-Silicon, Origin, Sino-Akeso, Tricida, LISCure

NK cell therapy company Artiva Biotherapeutics Inc. raised $120 million in a series B financing led by Venrock Healthcare Capital Partners. Other new investors participating included Acuta Capital Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton, Janus Henderson Investors, Logos Capital, RTW Investments, Citadel’s Surveyor Capital and Wellington Management Co.

Roivant buying computational drug discovery play Silicon
Roivant Sciences Ltd. is buying Silicon Therapeutics for $450 million in Roivant equity. Silicon’s computational physics platform for in silico design and optimization of small molecules complements Roivant’s targeted protein degradation platform, according to Roivant, which plans to integrate the company with its affiliate VantAI...